New drug combo for rectal cancer patients who want to save their anus
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that has not spread to other organs and is within 10 cm of the anal opening.
- You are between 18 and 75 years old.
- Your cancer is MSS or MSI-low (a genetic type) or pMMR (a protein pattern).
- You have a good performance status (able to carry out daily activities, ECOG 0-1).
- You have not had any prior cancer treatment, immunotherapy, or radiation to the pelvis.
- Your blood counts, kidney, and liver function are within normal ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests a combination of focused radiation therapy given quickly, along with chemotherapy, targeted drugs, and immunotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve survival chances by treating the cancer aggressively before an operation.
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
This trial tests adding immunotherapy to standard radiation and chemotherapy for patients with locally advanced rectal cancer. The goal is to see if a personalized approach improves outcomes while sparing more normal tissue.
This trial tests a treatment plan that combines chemotherapy, immunotherapy, and radiation before surgery for patients with middle or low rectal cancer. The goal is to shrink the tumor enough to avoid removing the anus, preserving bowel function.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.